Lava Therapeutics Nv Expected To Post A Loss Of 36 Cents A Share: Earnings Preview

LAVA Therapeutics NV

16/08/2024 13:32

* LAVA Therapeutics NV  LVTX.OQ   LVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 20
(estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for LAVA Therapeutics NV is
for a
loss of 36 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $6.00​, above​ its last closing price of $1.82. ​​​

This summary was machine generated August 16 at 12:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)